Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NKTR – Nektar Therapeutics

Nektar Therapeutics
NKTR
$56.23
Name : Nektar Therapeutics
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,899,788,544.00
EPSttm : -7.93
finviz dynamic chart for NKTR
Nektar Therapeutics
$56.23
0.69%
$0.39
NKTR — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

13.4

Margin Of Safety %

Put/Call OI Ratio

0.53

EPS Next Q Diff

1.31

EPS Last/This Y

0.19

EPS This/Next Y

-3.02

Price

56.21

Target Price

153.25

Analyst Recom

1.2

Performance Q

-21.98

Upside

-294.7%

Beta

-0.76

Ticker: NKTR




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-05-11NKTR78.830.600.4448398
2026-05-12NKTR78.420.612.5548475
2026-05-13NKTR75.950.671.2551059
2026-05-14NKTR74.670.651.3550214
2026-05-15NKTR70.670.630.4649913
2026-05-18NKTR68.530.840.5728932
2026-05-19NKTR67.590.840.4929776
2026-05-20NKTR69.490.840.6030151
2026-05-21NKTR68.550.830.0330473
2026-05-22NKTR66.590.790.2330312
2026-05-26NKTR65.520.780.2530538
2026-05-27NKTR65.40.780.6330927
2026-05-28NKTR64.980.780.1032150
2026-05-29NKTR64.840.771.6332286
2026-06-02NKTR58.60.850.6336285
2026-06-03NKTR59.230.810.6237560
2026-06-04NKTR59.270.810.3538112
2026-06-05NKTR57.420.700.2636667
2026-06-08NKTR56.620.550.1336972
2026-06-09NKTR56.220.530.1137621
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-05-11NKTR78.7440.7- -8.71
2026-05-12NKTR78.4725.1- -9.44
2026-05-13NKTR75.9726.7- -9.44
2026-05-14NKTR74.3426.7- -9.54
2026-05-15NKTR70.7926.7- -9.54
2026-05-18NKTR68.4826.7- -9.54
2026-05-19NKTR67.5726.7- -9.54
2026-05-20NKTR69.4926.7- -9.54
2026-05-21NKTR68.5626.7- -9.54
2026-05-22NKTR66.6226.7- -9.54
2026-05-26NKTR65.6026.7- -9.54
2026-05-27NKTR65.4326.7- -9.54
2026-05-28NKTR64.9926.7- -9.54
2026-05-29NKTR64.8226.7- -9.54
2026-06-01NKTR63.8726.7- -9.54
2026-06-02NKTR58.6726.7- -9.54
2026-06-03NKTR59.2326.7- -9.54
2026-06-04NKTR59.3426.7- -9.54
2026-06-05NKTR57.3826.7- -9.54
2026-06-08NKTR56.6426.7- -9.54
2026-06-09NKTR56.2126.7- -9.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-05-11NKTR-1.1724.5511.17
2026-05-12NKTR-1.1724.5512.62
2026-05-13NKTR-1.1524.5512.41
2026-05-14NKTR-1.1524.5512.41
2026-05-15NKTR-1.1524.5512.41
2026-05-18NKTR-1.1523.1512.37
2026-05-19NKTR-1.3323.1512.37
2026-05-20NKTR-1.3323.1512.37
2026-05-21NKTR-1.3323.1512.59
2026-05-22NKTR-0.7623.1512.59
2026-05-26NKTR-0.4327.2912.59
2026-05-27NKTR-0.4327.2912.59
2026-05-28NKTR-0.4327.2913.40
2026-05-29NKTR-0.4327.2913.40
2026-06-02NKTR-0.4327.1613.40
2026-06-03NKTR-0.4327.1613.40
2026-06-04NKTR-0.4327.1613.40
2026-06-05NKTR-0.4327.1613.40
2026-06-08NKTR-0.4327.1613.40
2026-06-09NKTR-0.4327.1613.40
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-1.82

Avg. EPS Est. Current Quarter

-2.04

Avg. EPS Est. Next Quarter

-0.52

Insider Transactions

-0.43

Institutional Transactions

27.16

Beta

-0.76

Average Sales Estimate Current Quarter

10

Average Sales Estimate Next Quarter

10

Fair Value

Quality Score

33

Growth Score

23

Sentiment Score

47

Actual DrawDown %

80.7

Max Drawdown 5-Year %

-97.8

Target Price

153.25

P/E

Forward P/E

PEG

P/S

34.15

P/B

1.99

P/Free Cash Flow

EPS

-8.42

Average EPS Est. Cur. Y​

-9.54

EPS Next Y. (Est.)

-12.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-284.18

Relative Volume

1.15

Return on Equity vs Sector %

-54.9

Return on Equity vs Industry %

-38.8

EPS 1 7Days Diff

-1

EPS 1 30Days Diff

0.47

EBIT Estimation

NKTR Healthcare
$56.23
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
18/20
Pullback
13/25
Volume
4/15
Valuation
12/20
TP/AR
4/10
Options
7/10
RSI
21.2
Range 1M
6%
Sup Dist
1.6%
🚀
Momentum Growth
Ride accelerating trends
N/A
36 /100
WEAK
Momentum
7/25
Growth
12/30
Estimates
2/20
Inst/Vol
8/15
Options
7/10
EPS Yr
6.9%
EPS NY
-22.2%
52W%
47.3%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +172.5% upside
Quality
6/30
Valuation
16/30
Growth
6/25
Stability
7/10
LT Trend
3/5
Upside
+172.5%
Quality
33
Nektar Therapeutics
Sector: Healthcare
Industry: Biotechnology
Employees: 63
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
NKTR

Latest News

Caricamento notizie per NKTR
stock quote shares NKTR – Nektar Therapeutics Stock Price stock today
news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025
marketwatch NKTR – Nektar Therapeutics yahoo finance google finance
stock history NKTR – Nektar Therapeutics invest stock market
stock prices NKTR premarket after hours
ticker NKTR fair value insiders trading